top of page

Nutra Pharma Announces Additions to the Board of Directors and Management Team

August 16, 2016

Nutra Pharma is announcing the addition of Dan Oran to their Board of Directors and Dale Vanderputten, PhD as their Chief Scientific Officer

August 16, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today the appointment of Dan Oran as their newest member of their Board of Directors. They are also announcing the appointment of Dale Vanderputten, PhD as their Chief Scientific Officer (CSO).

"We have been working diligently at Nutra Pharma to put the right pieces in place to ensure growth and fulfill our business plan. This includes incremental revenue growth through the sales of our OTC pain therapies as well as pursuing clinical trials and eventual licensing of our drug products," commented Rik J Deitsch, CEO of Nutra Pharma. "Dan Oran is a visionary entrepreneur that will serve as an active Board member. Primarily, he will aid with the marketing and distribution of our therapy for pain and inflammation, Nyloxin; with early plans for retail distribution globally," he continued. "Dr. Vanderputten comes to us with over 30 years of management and clinical experience with governmental agencies as well as private sector biotech. As his first act as our CSO, he will spearhead our efforts to move our Multiple Sclerosis drug, RPI-78M, through the FDA approval process," he concluded.

Dan Oran was raised and educated in Israel, moving to the United States in 1990. He has more than 27 years of experience as a successful business owner in the US and Israel with extensive knowledge of finances, sales and cost management skills. Mr. Oran is also a seasoned Real Estate investor who owns and manages both commercial and residential properties in South Florida and abroad. Since 2014 he has been the brand builder and consultant for the Cybertec Group, a communications technology company. From 2008 through 2014 he owned and managed Aboulafia Since 1879, a manufacturer and distributor of electronics equipment. From 1999 through 2008, Mr. Oran owned and managed Lav Distributors, a distributor of electronics equipment. He will serve as an active Board member for Nutra Pharma with a focus on increasing the sales and distribution of Nyloxin® and Pet Pain-Away™

"Nutra Pharma is truly a diamond in the rough," stated Dan Oran - the newest Board member of Nutra Pharma. "The Company has great OTC products that work and simply need a proven distribution model to get those products into the hands of consumers that desperately need them," he continued. "I will be working closely with the management and Board of Nutra Pharma to expand distribution, grow sales and increase the Company's visibility. This is an exciting time for Nutra Pharma and the perfect opportunity for products like Nyloxin and Pet Pain-Away," he concluded.

Dale Vanderputten, PhD has been CEO and CSO of the biotechnology company Omnia Biologics, Inc., headquartered in Rockville, MD since 2003. From 1999 through 2003 he was COO and CSO of cancer gene therapy company DirectGene, Inc., headquartered in Annapolis, MD. Dr VanderPutten has held scientific and technology development positions in government, academia and industry from 1980 through 1999 including at the National Institutes of Health, University of Maryland, and Proteome Sciences, plc. Dr. VanderPutten received a Bachelor of Sciences degree in Biology and Chemistry from the American University in Washington, DC in 1982, a PhD in Genetics from the George Washington University in 1993 and an MBA from the University of Maryland in 1996. He did his doctoral and post-doctoral training in molecular neuro-biology at the National Institutes of Health. Dr. Vanderputten will begin his tenure as CSO by taking over Nutra Pharma's clinical product development. RPI-78M, the Company's therapy for Multiple Sclerosis, received Orphan Designation from the FDA for the treatment of Juvenile Multiple Sclerosis in September 2015. Dr. Vanderputten will work with our researchers and regulators to move RPI-78M through the clinical process for an eventual approval or licensing.

"The promise of medicines developed from venoms cannot be overstated," commented Dale Vanderputten, PhD - CSO of Nutra Pharma. "While science has just scratched the surface in understanding the biology of the 40,000 or so venomous creatures on earth, venom's contribution to human health has been tremendous," he continued. "Nutra Pharma is on the forefront of tapping the potential of this resource to address serious unmet medical needs and I am overjoyed to help with this important work," he concluded.

Nutra Pharma will announce further strategic business segment actions over the coming months.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™.

For additional information about Nutra Pharma, visit: or

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The additions of Dan Oran to the Board and Dale Vanderputten, PhD as the CSO should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. # # #

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
bottom of page